Financial insights of BIAF

MyFinsight

For the quarter ending 2025-09-30, BIAF made $1,446,066 in revenue. -$5,051,084 in net income. Net profit margin of -349.30%.

Unit: Dollar

Income Statement	2025-09-30	2025-06-30	2024-12-31	2024-09-30
Net revenue	1,446,066	1,269,483	2,306,992	2,350,386
Direct costs and expenses	942,211	1,016,602	1,567,803.5	1,440,158
Research and development	330,589	311,372	392,148.5	274,497
Clinical development	143,311	129,279	88,244	93,705
Selling, general and administrative	2,209,441	2,214,561	2,553,053	2,364,592
Depreciation and amortization	113,360	113,229	151,634.5	151,298
Total operating expenses	3,738,912	3,785,043	4,752,883.5	4,324,250
Loss from operations	-2,292,846	-2,515,560	-2,445,891.5	-1,973,864
Interest income	1,088	2,025	5,098	2,228
Interest expense	5,358	10,460	24,297.5	21,631
Other income	513	38,053	213.333	9,683
Other expense	3,839	483,043	-1,501	14,697
Change in fair value of warrants issued	2,747,460	1,062,818	-	-
Total other income (expense), net	-2,755,056	-1,516,243	-	-24,417
Net loss before provision for income tax expense	-5,047,902	-4,031,803	-2,462,520	-1,998,281
Provision for income tax expense	3,182	28,984	1,836	2,559
Net loss	-5,051,084	-4,060,787	-2,464,356	-2,000,840

Net loss per common share, basic	-4.74	-0.17	-0.2	-0.16
Net loss per common share, diluted	-4.74	-0.17	-0.2	-0.16
Weighted average common shares outstanding, basic	1,066,350	24,021,546	-5,828,073	12,391,867
Weighted average common shares outstanding, diluted	1,066,350	24,021,546	-5,828,073	12,391,867